406 related articles for article (PubMed ID: 27463625)
1. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT.
Kniggendorf VF; Novais EA; Kniggendorf SL; Xavier C; Cole ED; Regatieri CV
Arq Bras Oftalmol; 2016; 79(3):155-8. PubMed ID: 27463625
[TBL] [Abstract][Full Text] [Related]
2. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
Savur F; Kaldırım H; Atalay K; Korkmaz Ş
Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
[TBL] [Abstract][Full Text] [Related]
3. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
4. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J
Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844
[TBL] [Abstract][Full Text] [Related]
5. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
[TBL] [Abstract][Full Text] [Related]
6. Effect of intravitreal dexamethasone implant on retinal and choroidal thickness in refractory diabetic macular oedema after multiple anti-VEGF injections.
Kim M; Cho YJ; Lee CH; Lee SC
Eye (Lond); 2016 May; 30(5):718-25. PubMed ID: 26939558
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
Okamoto M; Yamashita M; Ogata N
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
[TBL] [Abstract][Full Text] [Related]
8. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
Campos A; Campos EJ; do Carmo A; Patrício M; Castro de Sousa JP; Ambrósio AF; Silva R
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
[TBL] [Abstract][Full Text] [Related]
9. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
Chang CK; Cheng CK; Peng CH
Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
11. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
12. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Kim H; Lee SC; Kwon KY; Lee JH; Koh HJ; Byeon SH; Kim SS; Kim M; Lee CS
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1497-1503. PubMed ID: 26626772
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
Cetin EN; Demirtaş Ö; Özbakış NC; Pekel G
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1801-1806. PubMed ID: 29922890
[TBL] [Abstract][Full Text] [Related]
15. Retinal Layers Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Anti-VEGF Agents: Long-Term Outcomes of a Spectral-Domain OCT Study.
Chatziralli I; Kazantzis D; Theodossiadis G; Theodossiadis P; Sergentanis TN
Ophthalmic Res; 2021; 64(2):230-236. PubMed ID: 32564022
[TBL] [Abstract][Full Text] [Related]
16. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
18. Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab.
Sizmaz S; Kucukerdonmez C; Kal A; Pinarci EY; Canan H; Yilmaz G
Eur J Ophthalmol; 2014; 24(6):904-10. PubMed ID: 24803153
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment.
Giacomelli G; Finocchio L; Biagini I; Sodi A; Murro V; Introini U; Varano M; Bandello F; Menchini U
Ophthalmologica; 2017; 238(1-2):44-51. PubMed ID: 28641290
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema.
Yiu G; Manjunath V; Chiu SJ; Farsiu S; Mahmoud TH
Am J Ophthalmol; 2014 Oct; 158(4):745-751.e2. PubMed ID: 24952275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]